UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 13,
2020
Edesa Biotech, Inc.
(Exact Name of Registrant as Specified in its
Charter)
|
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|||
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
|
||||
|
(Address
of Principal Executive Offices)
|
||||
(289) 800-9600
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
|
Common
Shares
|
|
EDSA
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
|
|
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On May 13, 2020, Edesa
Biotech, Inc. (the “Company”) held its 2020 annual
general meeting of shareholders (the “Annual
Meeting”). At the Annual
Meeting, 5,514,095 common shares, or approximately 62% of the
outstanding common shares entitled to vote, were represented by
proxy or in person. Set forth below are the
matters submitted to the shareholders at the Annual Meeting, all of
which were approved:
|
|
●
|
the election of seven directors, nominated by the Company’s
board of directors, to serve until the Company’s annual
meeting of shareholders to be held in 2021 or until their
successors are duly elected and qualified (“Proposal No. 1”);
and
|
|
|
●
|
the appointment of MNP LLP as the Company’s
auditors and independent registered public accounting firm for the
ensuing year (“Proposal
No. 2”).
|
The
final voting results for each matter submitted to a vote of the
Company’s shareholders are as follows:
Proposal No. 1. Election of the Company’s
Directors.
Proposal
to elect seven directors to the Board:
|
|
For
|
Withhold
|
Broker
Non-Votes
|
|
Lorin
Johnson, PhD
|
4,331,219
|
5,266
|
1,177,610
|
|
Sean
MacDonald
|
4,327,319
|
9,166
|
1,177,610
|
|
Pardeep
Nijhawan, MD
|
4,326,716
|
9,769
|
1,177,610
|
|
Frank
Oakes
|
4,328,602
|
7,883
|
1,177,610
|
|
Paul
Pay
|
4,327,291
|
9,194
|
1,177,610
|
|
Carlo
Sistilli, CPA, CMA
|
4,326,467
|
10,018
|
1,177,610
|
|
Peter
van der Velden
|
4,327,420
|
9,065
|
1,177,610
|
Proposal No. 2. Appointment of Independent Registered Public
Accounting Firm.
Proposal to approve the appointment of MNP
LLP as the Company’s
auditors and independent registered public accounting firm for the
ensuing year.
|
For
|
Withhold
|
Broker
Non-Votes
|
|
5,491,379
|
22,716
|
0
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Edesa
Biotech, Inc.
|
|
|
|
|
|
|
Date:
May 14, 2020
|
By:
|
/s/
Kathi Niffenegger
|
|
|
Name:
|
Kathi
Niffenegger
|
|
|
Title:
|
Chief
Financial Officer
|